컨퍼런스 커버리지 | 학술센터 | 킴스온라인

주요메뉴 바로가기
본문 바로가기
하단메뉴 바로가기

최근 해외학술대회의 주요 발표내용을 제공합니다.

컨퍼런스 커버리지

European Alliance of Associations for Rheumatology Annual Congress (EULAR 2025)

11 June - 14 June, 2025, Spain

Add-on obinutuzumab yields robust treatment benefit in lupus nephritis

2025-09-17

In a post hoc analysis using the phase III REGENCY study dataset, obinutuzumab on top of standard therapy (ST) demonstrates significant superiority to placebo plus ST across numerous renal response definitions in patients with active lupus nephritis (LN).
Bimekizumab shows long-term benefits across axSpA spectrum

2025-09-17

Treatment with bimekizumab showed sustained efficacy for up to 3 years in patients with nonradiographic (nr) and radiographic (r) axial spondyloarthritis (axSpA), based on a pooled analysis of the two phase III studies (BE MOBILE 1 and 2) and combined open-label extension (OLE) study presented at EULAR 2025.
Deucravacitinib delivers superior efficacy, safety in active PsA

2025-09-17

Deucravacitinib exhibits superiority over placebo in terms of overall disease activity measures, musculoskeletal and dermatologic manifestations, and quality of life in adults with active psoriatic arthritis (PsA) who are naive to biologic disease-modifying antirheumatic drugs (DMARDs), according to the results of the POETYK PsA-1 study.
GLP-1 RAs show signal of benefit in fibromyalgia

2025-09-17

New research suggests that glucagon-like peptide-1 receptor agonists (GLP-1 RAs), commonly used for diabetes and obesity, may hold therapeutic potential for patients with fibromyalgia.
Inebilizumab reduces flare risk in IgG4-RD patients across demographics

2025-09-17

Treatment with inebilizumab reduced the risk of disease flares in patients with immunoglobulin G4-related disease (IgG4-RD) irrespective of sex, age, or race, according to a subgroup analysis of the phase III MITIGATE study presented at EULAR 2025.
MOSAIC updates: MRI outcomes bolster apremilast role in PsA dactylitis

2025-09-17

Apremilast, an oral immunomodulating phosphodiesterase-4 inhibitor, reduces inflammation in individual joints and clinical dactylitis as per MRI in patients with psoriatic arthritis (PsA), according to the results of a dynamic contrast-enhanced MRI (DCE-MRI) analysis of the phase IV, open-label MOSAIC study.
Nerandomilast safe, effective in autoimmune disease-related PPF

2025-09-17

Treatment with nerandomilast demonstrates efficacy in slowing forced vital capacity (FVC) decline in patients with autoimmune interstitial lung disease (ILD) similar to that seen in the overall trial population, reveals a subgroup analysis of the FIBRONEER-ILD study.
Novel CD40L inhibitor excels in reaching lupus goal of care

2025-09-17

Adding the novel CD40L inhibitor dapirolizumab pegol (DZP) to standard of care appears to help patients with systemic lupus erythematosus (SLE) achieve low disease activity and remission, according to a prespecified secondary outcome analysis of the phase III PHOENYCS GO trial.
RA onset delayed through 4 years with 1-year abatacept treatment in at-risk individuals

2025-09-17

A 12-month therapeutic intervention with self-administered abatacept can delay the onset of rheumatoid arthritis (RA) in at-risk individuals for up to 4 years, according to results from the ALTO follow-up study presented at EULAR 2025.

1

최근 본 콘텐츠

최근 본 콘텐츠가 없습니다

TOP

주식회사 킴스

주식회사 킴스 | 광고/제휴문의 | 이용약관 | 개인정보처리방침 | 법적 책임의 한계 | 서비스 전체보기

서울특별시 강남구 테헤란로 8길 33 청원빌딩 1층 (주)킴스
개인정보관리책임자 : 최동섭 사업자등록번호 : 214-81-75415 통신판매업신고 : 강남-5166호 대표이사 : 마사키 타카하타
고객센터 : 1544-2930 (10:00~17:00, 주말/공휴일 제외) 팩스 : 02-3019-9380 e-mail : webmaster@kims.co.kr

Copyright © 1987-2025 KIMS Co., Ltd All Rights Reserved

KIMS 페이스북

KIMS 유튜브